Bagdade J D, Buchanan W F, Pollare T, Lithell H
Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.
Eur J Clin Pharmacol. 1996;49(5):355-9. doi: 10.1007/BF00203777.
Effective antihypertensive agents may differ in their capacity to reduce cardiovascular risk because they induce potentially atherogenic alterations in lipoprotein composition.
To assess this possibility, the effects of five months' treatment with either hydrochlorothiazide (HCTZ) or the converting enzyme inhibitor captopril (CAPT) on lipoprotein lipid composition were compared in thirty normolipidaemic patients with essential hypertension (EH).
The sixteen patients treated with HCTZ showed the expected directional alterations in plasma TG (+31%), HDL2-C (-16%), and CHOL (+7.6%); in contrast TG and CHOL were unchanged after captopril in fourteen patients and their HDL2-C declined (-16%). Neither drug altered lipoprotein core lipid composition, but small increases were observed in the HDL2 sphingomyelin/lecithin ratio after both agents. The plasma free (unesterified) cholesterol (FC) lecithin (L) ratio, a new index of cardiovascular risk, was abnormally increased before treatment and was not altered by either drug.
These findings indicate that HCTZ and CAPT treatment have small, but demonstrable effects on lipoprotein surface lipid composition in patients with EH that are confined to the HDL2 subfraction.
有效的抗高血压药物在降低心血管风险的能力上可能存在差异,因为它们可能会引起脂蛋白组成中潜在的致动脉粥样硬化改变。
为评估这种可能性,在30例原发性高血压(EH)的血脂正常患者中,比较了使用氢氯噻嗪(HCTZ)或转换酶抑制剂卡托普利(CAPT)治疗五个月对脂蛋白脂质组成的影响。
接受HCTZ治疗的16例患者血浆甘油三酯(TG)升高(+31%)、高密度脂蛋白2胆固醇(HDL2-C)降低(-16%)、胆固醇(CHOL)升高(+7.6%),呈现预期的变化趋势;相比之下,接受卡托普利治疗的14例患者的TG和CHOL未发生变化,HDL2-C降低(-16%)。两种药物均未改变脂蛋白核心脂质组成,但两种药物治疗后HDL2鞘磷脂/卵磷脂比值均有小幅升高。血浆游离(未酯化)胆固醇(FC)与卵磷脂(L)的比值是一种新的心血管风险指标,治疗前异常升高,且两种药物均未改变该指标。
这些发现表明,HCTZ和CAPT治疗对EH患者脂蛋白表面脂质组成有微小但可证实的影响,且仅限于HDL2亚组分。